27748842|t|Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in hepatocellular carcinoma
27748842|a|Hepatocellular carcinoma (HCC) remains one of the most common types of cancer worldwide and prognosis remains poor. Previous studies have suggested that long non‑coding RNAs (lncRNAs) may be key regulators of tumor development and progression in HCC. It has been determined that 61‑72% of transcribed regions contain lncRNAs in the antisense orientation (aslncRNAs). However, the function of aslncRNAs in HCC remains to be elucidated. The present study investigated the function of the aslncRNA zinc finger E‑box binding homeobox 2 antisense RNA 1 (ZEB2‑AS1) in 40 HCC tissues and 5 different human HCC cell lines using reverse transcription‑quantitative polymerase chain reaction. Additionally, the expression levels of ZEB2‑AS1 were downregulated by transfection of small interfering RNAs (siRNAs) to determine whether ZEB2‑AS1 is capable of affecting cell proliferation, invasion and metastasis by regulating ZEB2, vimentin, fibronectin, E‑cadherin and N‑cadherin expression levels. The results of the present study demonstrated that the expression levels of ZEB2‑AS1 were greater in HCC tissues when compared with the adjacent normal tissues. Furthermore, ZEB2‑AS1 expression was significantly associated with the size of the primary tumor, intrahepatic metastasis and tumor-node-metastasis stage. The Kaplan‑Meier survival curves suggested that patients with high ZEB2‑AS1 expression levels experienced the lowest overall and recurrence‑free survival rates compared with those that had low expression levels. In addition, the current study demonstrated that the downregulation of ZEB2‑AS1 was associated with decreased tumor growth and metastasis in HCC by the regulation of the expression levels of epithelial mesenchymal transition - induced markers. In conclusion, lncRNA ZEB2‑AS1 may be used as a valuable biomarker in patients with HCC.
27748842	0	14	Downregulation	T038	UMLS:C0013081
27748842	18	26	ZEB2-AS1	T017	UMLS:C2829215
27748842	54	64	metastasis	T038	UMLS:C0027627
27748842	68	92	hepatocellular carcinoma	T038	UMLS:C2239176
27748842	93	117	Hepatocellular carcinoma	T038	UMLS:C2239176
27748842	119	122	HCC	T038	UMLS:C2239176
27748842	164	170	cancer	T038	UMLS:C0006826
27748842	185	207	prognosis remains poor	T033	UMLS:C0278252
27748842	246	266	long non‑coding RNAs	T103	UMLS:C3494264
27748842	268	275	lncRNAs	T103	UMLS:C3494264
27748842	302	307	tumor	T038	UMLS:C0027651
27748842	324	335	progression	T038	UMLS:C0178874
27748842	339	342	HCC	T038	UMLS:C2239176
27748842	382	393	transcribed	T038	UMLS:C0040649
27748842	394	401	regions	T082	UMLS:C0205147
27748842	410	417	lncRNAs	T103	UMLS:C3494264
27748842	448	457	aslncRNAs	T103	UMLS:C3494264
27748842	485	494	aslncRNAs	T103	UMLS:C3494264
27748842	498	501	HCC	T038	UMLS:C2239176
27748842	579	587	aslncRNA	T103	UMLS:C3494264
27748842	588	640	zinc finger E‑box binding homeobox 2 antisense RNA 1	T017	UMLS:C2829215
27748842	642	650	ZEB2‑AS1	T017	UMLS:C2829215
27748842	658	661	HCC	T038	UMLS:C2239176
27748842	662	669	tissues	T017	UMLS:C0475358
27748842	686	691	human	T204	UMLS:C0086418
27748842	692	695	HCC	T038	UMLS:C2239176
27748842	696	706	cell lines	T017	UMLS:C0085983
27748842	713	773	reverse transcription‑quantitative polymerase chain reaction	T062	UMLS:C1514628
27748842	814	822	ZEB2‑AS1	T017	UMLS:C2829215
27748842	828	841	downregulated	T038	UMLS:C0013081
27748842	845	857	transfection	T038	UMLS:C0314641
27748842	861	883	small interfering RNAs	T103	UMLS:C1099354
27748842	885	891	siRNAs	T103	UMLS:C1099354
27748842	914	922	ZEB2‑AS1	T017	UMLS:C2829215
27748842	947	965	cell proliferation	T038	UMLS:C0596290
27748842	967	975	invasion	T038	UMLS:C2699153
27748842	980	990	metastasis	T038	UMLS:C0027627
27748842	1005	1009	ZEB2	T103	UMLS:C1505468
27748842	1011	1019	vimentin	T103	UMLS:C0042666
27748842	1021	1032	fibronectin	T103	UMLS:C0016055
27748842	1034	1044	E‑cadherin	T103	UMLS:C0042172
27748842	1049	1059	N‑cadherin	T103	UMLS:C0027215
27748842	1155	1163	ZEB2‑AS1	T017	UMLS:C2829215
27748842	1180	1183	HCC	T038	UMLS:C2239176
27748842	1184	1191	tissues	T017	UMLS:C0475358
27748842	1224	1238	normal tissues	T017	UMLS:C0040300
27748842	1253	1261	ZEB2‑AS1	T017	UMLS:C2829215
27748842	1262	1272	expression	T038	UMLS:C0017262
27748842	1311	1336	size of the primary tumor	T082	UMLS:C0475440
27748842	1338	1350	intrahepatic	T082	UMLS:C1512948
27748842	1351	1361	metastasis	T038	UMLS:C0027627
27748842	1366	1393	tumor-node-metastasis stage	T170	UMLS:C1302362
27748842	1462	1470	ZEB2‑AS1	T017	UMLS:C2829215
27748842	1660	1674	downregulation	T038	UMLS:C0013081
27748842	1678	1686	ZEB2‑AS1	T017	UMLS:C2829215
27748842	1734	1744	metastasis	T038	UMLS:C0027627
27748842	1748	1751	HCC	T038	UMLS:C2239176
27748842	1798	1831	epithelial mesenchymal transition	T038	UMLS:C1523298
27748842	1842	1849	markers	T201	UMLS:C0005516
27748842	1866	1872	lncRNA	T103	UMLS:C3494264
27748842	1873	1881	ZEB2‑AS1	T017	UMLS:C2829215
27748842	1908	1917	biomarker	T201	UMLS:C0005516
27748842	1935	1938	HCC	T038	UMLS:C2239176